Francisco Javier
López Jiménez
Profesor/a Asociado/a en CC. de la Salud
Hospital Clinic Barcelona
Barcelona, EspañaPublications in collaboration with researchers from Hospital Clinic Barcelona (28)
2024
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain
Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
Frontiers in Immunology, Vol. 14
-
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Vol. 13, Núm. 1
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
2022
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
2021
-
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group
Transplant Infectious Disease, Vol. 23, Núm. 4
-
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study
Cancer Medicine, Vol. 10, Núm. 21, pp. 7629-7640
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620
-
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471
-
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831
2016
-
Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136
2014
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
-
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307
-
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation
Haematologica, Vol. 99, Núm. 10, pp. 1632-1637